Where Will Eli Lilly Be in 3 Years?

Eli Lilly continues to demonstrate robust growth, primarily fueled by its blockbuster weight-loss drugs, Mounjaro and Zepbound, which saw sales increase by 68% and 172% respectively in the latest quarter, totaling over $8 billion and compensating for declines in older drugs like Trulicity. Despite investor concern over its oral weight-loss candidate orforglipron, which showed 12.4% weight loss compared to tirzepatide's 15% efficacy and led to a 14% stock dip, Lilly plans regulatory submission this year, banking on its convenience and broader accessibility to meet high market demand. With orforglipron and the advanced triple-pathway candidate retatrutide in Phase 3, Lilly is strategically positioned to dominate the burgeoning weight-loss market, forecast to reach $95 billion by 2030.

Analysis

Eli Lilly's robust growth trajectory is underpinned by its dominant position in the weight-loss drug market, with tirzepatide-based products Mounjaro and Zepbound delivering exceptional quarterly sales growth of 68% and 172% to over $5 billion and $3 billion, respectively. This performance is critical as it successfully counteracts declining revenue from the older blockbuster Trulicity, which faces patent expiration in 2027. The company's pipeline holds significant potential, though it has introduced a point of contention for investors. The oral weight-loss candidate, orforglipron, demonstrated 12.4% average weight loss in its Attain-1 trial, a figure lower than the 15% efficacy shown by injectable tirzepatide. This efficacy gap triggered a 14% decline in LLY shares post-announcement, reflecting investor concern. However, the strategic value of an oral drug—being cheaper and easier to manufacture and distribute—could be substantial in a market characterized by high demand and previous supply shortages. Furthermore, Lilly is advancing retatrutide, a triple-pathway candidate in Phase 3 trials that may offer superior efficacy, positioning the company to capture a significant share of a market forecast by Goldman Sachs to reach $95 billion by 2030.

Key Decisions for Investors

• Investors should assess the market's negative reaction to orforglipron's efficacy as a potential over-reaction, weighing the lower efficacy against the strategic advantages of an oral formulation in terms of market access, manufacturing cost, and patient convenience.
• Monitor key upcoming catalysts, including the planned regulatory submission for orforglipron this year and the release of Phase 3 trial data for the next-generation candidate retatrutide, which could reaffirm or challenge Lilly's long-term leadership in the obesity market.
• Consider that the powerful cash flow from Mounjaro and Zepbound provides a substantial buffer, funding extensive R&D and mitigating risks associated with the patent cliff for Trulicity and pipeline development uncertainties.
• Evaluate Lilly's valuation in the context of its dominant current portfolio and its multi-pronged strategy to lead the $95 billion projected weight-loss market, rather than focusing solely on the success of a single pipeline candidate.